Loading...
•
Mar 31, 2023
Day One Q1 2023 Earnings Report
Announced first quarter 2023 financial results and highlighted recent corporate achievements.
Key Takeaways
Day One Biopharmaceuticals reported its first quarter 2023 financial results, featuring a cash position of $318.2 million, R&D expenses of $27.8 million, G&A expenses of $18.0 million, and a net loss of $42.4 million.
FIREFLY-1 clinical abstract selected for oral presentation at the 2023 ASCO Annual Meeting
Leadership team strengthened with executive appointments in clinical development and commercialization
Pre-New Drug Application (NDA) meeting held April 19, 2023 with U.S. Food and Drug Administration (FDA) for tovorafenib (DAY101) for relapsed or progressive pediatric low-grade glioma (pLGG)
Company to host conference call on June 4th at 6:00 PM CT
Forward Guidance
Day One’s current operating plan, management believes it has sufficient capital resources to fund anticipated operations into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...